HKU Scholars Hub: Browsing DSpace

Browsing by Author Brady, JC

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 中

or enter first few letters:

Showing results 1 to 9 of 9

	Title	Author(s)	Issue Date	Views
	A phase II study of capecitabine, oxaliplatin, and bevacizumab in the treatment of metastatic esophagogastric adenocarcinomas Journal:Oncologist	Uronis, HE Bendell, JC Altomare, I Blobe, GC David Hsu, S Morse, MA Pang, H Yousuf Zafar, S Conkling, P Favaro, J Arrowood, CC Cushman, SM Meadows, KL Brady, JC Nixon, AB Hurwitz, HI	2013	75
	Biomarker modulation in patients (pts) receiving TRC105 (T) and bevacizumab (B) in a phase Ib clinical trial Proceeding/Conference:Journal of Clinical Oncology	Liu, Y Clarke, J Starr, MD Brady, JC Pang, HMH Rushing, C Alvarez, D Adams, BJ Theuer, CP Hurwitz, H Nixon, AB	2014
	Blood-based markers of efficacy and resistance to cetuximab treatment in metastatic colorectal cancer: results from CALGB 80203 (Alliance) Journal:Cancer Medicine	Hatch, AJ Sibley, AB Starr, MD Brady, JC Jiang, C Jia, J Bowers, DL Pang, H Owzar, K Niedzwiecki, D Innocenti, F Venook, AP Hurwitz, HI Nixon, AB The Alliance for Clinical Trials in Oncology	2016	30
	Modulation of angiogenic biomarkers in patients receiving high-dose TRC105 Proceeding/Conference:Journal of Clinical Oncology	Liu, Y Starr, M Brady, JC Pang, HMH Dellinger, A Leigh, BR Theuer, CP Hurwitz, H Nixon, AB	2012	49
	Modulation of circulating protein biomarkers following TRC105 (anti-endoglin antibody) treatment in patients with advanced cancer Journal:Cancer Medicine	Liu, Y Starr, MD Brady, JC Dellinger, A Pang, HMH Adams, B Theuer, CP Lee, NY Hurwitz, HI Nixon, AB	7-Mar-2014	68
	Modulation of Circulating Protein Biomarkers in Cancer Patients Receiving Bevacizumab and the Anti-Endoglin Antibody, TRC105 Journal:Molecular Cancer Therapeutics	Liu, Y Starr, MD Brady, JC Rushing, C Pang, H Adams, B Alvarez, D Theuer, CP Hurwitz, HI Nixon, AB	2018	15
	Phase I study of capecitabine, oxaliplatin, bevacizumab, and everolimus in advanced solid tumors Journal:Invest New Drugs	Rangwala, F Bendell, JC Kozloff, MF Arrowood, CC Dellinger, A Meadows, J Tourt-Uhlig, S Murphy, J Meadows, KL Starr, A Broderick, S Brady, JC Cushman, SM Morse, MA Uronis, HE Hsu, SD Zafar, SY Wallace, J Starodub, AN Strickler, JH Pang, HMH Nixon, AB Hurwitz, HI	2014	59
	Phase I study of dasatinib in combination with capecitabine, oxaliplatin and bevacizumab followed by an expanded cohort in previously untreated metastatic colorectal cancer Journal:Investigational New Drugs	Strickler, JH McCall, S Nixon, AB Brady, JC Pang, H Rushing, C Cohn, A Starodub, A Arrowood, C Haley, S Meadows, KL Morse, MA Uronis, HE Blobe, GC Hsu, SD Zafar, SY Hurwitz, HI	2014	61
	Prognostic and predictive blood-based biomarkers of overall survival (OS) in patients (pts) with advanced colorectal cancer (CRC) treated with cetuximab (C): Results from CALGB 80203 (Alliance) Proceeding/Conference:Journal of Clinical Oncology	Hatch, AJ Pang, HMH Starr, MD Brady, JC Jia, J Chen, J Sibley, A Owzar, K Niedzwiecki, D Venook, AP Cushman, SM Hurwitz, H Nixon, AB	2014

Showing results 1 to 9 of 9